140 related articles for article (PubMed ID: 37830752)
61. Mechanism of Fcγ receptor-mediated trogocytosis-based false-positive results in flow cytometry.
Masuda S; Iwasaki S; Tomaru U; Sato J; Kawakami A; Ichijo K; Sogo S; Baba T; Katsumata K; Kasahara M; Ishizu A
PLoS One; 2012; 7(12):e52918. PubMed ID: 23300821
[TBL] [Abstract][Full Text] [Related]
62. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
[TBL] [Abstract][Full Text] [Related]
63. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Cheson BD
J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041
[TBL] [Abstract][Full Text] [Related]
64. The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies.
Markovič T; Podgornik H; Avsec D; Nabergoj S; Mlinarič-Raščan I
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163524
[TBL] [Abstract][Full Text] [Related]
65. The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell.
Daubeuf S; Lindorfer MA; Taylor RP; Joly E; Hudrisier D
J Immunol; 2010 Feb; 184(4):1897-908. PubMed ID: 20089699
[TBL] [Abstract][Full Text] [Related]
66. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
67. Obinutuzumab for chronic lymphocytic leukemia.
Rioufol C; Salles G
Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
[TBL] [Abstract][Full Text] [Related]
68. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
Lara S; Heilig J; Virtanen A; Kleinau S
BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
[TBL] [Abstract][Full Text] [Related]
69. Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors.
Gryzik M; Grzywocz Z; Wasilewska D; Kawiak J; Stachowiak R; Bielecki J; Hoser G
Int J Immunopathol Pharmacol; 2015 Sep; 28(3):329-40. PubMed ID: 26216910
[TBL] [Abstract][Full Text] [Related]
70. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.
Li Y; Williams ME; Cousar JB; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2007 Sep; 179(6):4263-71. PubMed ID: 17785867
[TBL] [Abstract][Full Text] [Related]
71. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.
Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; de Jong RN; Beurskens FJ; Schuurman J; Parren PW; Taylor RP
Mol Immunol; 2016 Feb; 70():13-23. PubMed ID: 26690706
[TBL] [Abstract][Full Text] [Related]
72. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.
Bagacean C; Zdrenghea M; Tempescul A; Cristea V; Renaudineau Y
Immunotherapy; 2016 May; 8(5):569-81. PubMed ID: 27140410
[TBL] [Abstract][Full Text] [Related]
73. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.
Korycka-Wołowiec A; Wołowiec D; Robak T
Expert Opin Drug Saf; 2015; 14(12):1945-59. PubMed ID: 26566719
[TBL] [Abstract][Full Text] [Related]
74. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
[TBL] [Abstract][Full Text] [Related]
75. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J
Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523
[TBL] [Abstract][Full Text] [Related]
76. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.
Beum PV; Kennedy AD; Taylor RP
J Immunol Methods; 2004 Jun; 289(1-2):97-109. PubMed ID: 15251416
[TBL] [Abstract][Full Text] [Related]
77. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.
Taylor RP; Lindorfer MA
Curr Opin Immunol; 2008 Aug; 20(4):444-9. PubMed ID: 18585457
[TBL] [Abstract][Full Text] [Related]
78. False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay.
Chen K; Page JG; Schwartz AM; Lee TN; DeWall SL; Sikkema DJ; Wang C
J Immunol Methods; 2013 Aug; 394(1-2):22-31. PubMed ID: 23639298
[TBL] [Abstract][Full Text] [Related]
79. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
VanDerMeid KR; Elliott MR; Baran AM; Barr PM; Chu CC; Zent CS
Cancer Immunol Res; 2018 Oct; 6(10):1150-1160. PubMed ID: 30089638
[TBL] [Abstract][Full Text] [Related]
80. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies.
Gertner-Dardenne J; Bonnafous C; Bezombes C; Capietto AH; Scaglione V; Ingoure S; Cendron D; Gross E; Lepage JF; Quillet-Mary A; Ysebaert L; Laurent G; Sicard H; Fournié JJ
Blood; 2009 May; 113(20):4875-84. PubMed ID: 19278954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
